{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:58:24Z","timestamp":1723078704421},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T00:00:00Z","timestamp":1384387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00277-013-1934-7","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T08:27:02Z","timestamp":1384331222000},"page":"147-156","source":"Crossref","is-referenced-by-count":5,"title":["Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17\u00a0years\u2019 experience in a single centre"],"prefix":"10.1007","volume":"93","author":[{"given":"Sinziana","family":"Radesi-Sarghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavie","family":"Arbion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dartigeas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Delain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotfi","family":"Benboubker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"H\u00e9rault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,14]]},"reference":[{"issue":"11","key":"1934_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 89(11):3909\u20133918","journal-title":"Blood"},{"issue":"10","key":"1934_CR2","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study G (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064\u20133071. doi: 10.1182\/blood-2004-04-1323","journal-title":"Blood"},{"issue":"17","key":"1934_CR3","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010) Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol Off J Am Soc Clin Oncol 28(17):2853\u20132858. doi: 10.1200\/JCO.2009.26.5827","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"1934_CR4","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","volume":"96","author":"S Gouill Le","year":"2011","unstructured":"Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica 96(8):1128\u20131135. doi: 10.3324\/haematol.2010.030320","journal-title":"Haematologica"},{"issue":"8","key":"1934_CR5","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood.V91.8.3017.3017_3017_3027","volume":"91","author":"PM Grimley","year":"1998","unstructured":"Grimley PM, Fang H, Rui H, Petricoin EF 3rd, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J (1998) Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood 91(8):3017\u20133027","journal-title":"Blood"},{"issue":"12","key":"1934_CR6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1089\/107999000750053799","volume":"20","author":"N Yanase","year":"2000","unstructured":"Yanase N, Ohshima K, Ikegami H, Mizuguchi J (2000) Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interf Cytokine Res Off J Int Soc Interf Cytokine Res 20(12):1121\u20131129. doi: 10.1089\/107999000750053799","journal-title":"J Interf Cytokine Res Off J Int Soc Interf Cytokine Res"},{"issue":"3","key":"1934_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","volume":"8","author":"M Chawla-Sarkar","year":"2003","unstructured":"Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis Int J Program Cell Death 8(3):237\u2013249","journal-title":"Apoptosis Int J Program Cell Death"},{"issue":"2","key":"1934_CR8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435\u2013445","journal-title":"Blood"},{"issue":"22","key":"1934_CR9","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","volume":"329","author":"P Solal-Celigny","year":"1993","unstructured":"Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P et al (1993) Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. N Engl J Med 329(22):1608\u20131614. doi: 10.1056\/NEJM199311253292203","journal-title":"N Engl J Med"},{"issue":"1","key":"1934_CR10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002371-200101000-00007","volume":"24","author":"IE Allen","year":"2001","unstructured":"Allen IE, Ross SD, Borden SP, Monroe MW, Kupelnick B, Connelly JE, Ozer H (2001) Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin\u2019s lymphoma. J Immunother 24(1):58\u201365","journal-title":"J Immunother"},{"issue":"10","key":"1934_CR11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","volume":"23","author":"AZ Rohatiner","year":"2005","unstructured":"Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 23(10):2215\u20132223. doi: 10.1200\/JCO.2005.06.146","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1934_CR12","volume":"1","author":"P Baldo","year":"2010","unstructured":"Baldo P, Rupolo M, Compagnoni A, Lazzarini R, Bearz A, Cannizzaro R, Spazzapan S, Truccolo I, Moja L (2010) Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev 1, CD004629. doi: 10.1002\/14651858.CD004629.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1934_CR13","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol Off J Am Soc Clin Oncol 16(8):2825\u20132833","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"1934_CR14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","volume":"23","author":"P Colombat","year":"2012","unstructured":"Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P (2012) Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol Off J Eur Soc Med Oncol \/ ESMO 23(9):2380\u20132385. doi: 10.1093\/annonc\/mds177","journal-title":"Ann Oncol Off J Eur Soc Med Oncol \/ ESMO"},{"issue":"1","key":"1934_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97(1):101\u2013106","journal-title":"Blood"},{"issue":"7","key":"1934_CR16","first-page":"2644","volume":"6","author":"TA Davis","year":"2000","unstructured":"Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ, Dowden S, Levy R (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res Off J Am Assoc Cancer Res 6(7):2644\u20132652","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"1934_CR17","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","volume":"17","author":"TA Davis","year":"1999","unstructured":"Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab. J Clin Oncol Off J Am Soc Clin Oncol 17(6):1851\u20131857","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9759","key":"1934_CR18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferme C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42\u201351. doi: 10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet"},{"issue":"6","key":"1934_CR19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol Off J Am Soc Clin Oncol 23(6):1088\u20131095. doi: 10.1200\/JCO.2005.12.191","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"1934_CR20","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","volume":"104","author":"G Cartron","year":"2004","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9):2635\u20132642. doi: 10.1182\/blood-2004-03-1110","journal-title":"Blood"},{"issue":"1","key":"1934_CR21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10428190701704647","volume":"49","author":"E Kimby","year":"2008","unstructured":"Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Linden O, Sundstrom C, Nordic Lymphoma G (2008) Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 49(1):102\u2013112. doi: 10.1080\/10428190701704647","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"1934_CR22","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol Off J Am Soc Clin Oncol 18(17):3135\u20133143","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1934_CR23","doi-asserted-by":"crossref","unstructured":"Hossfeld DK (2002) E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Ann Oncol 13 (3):490\u2013491. doi: 10.1093\/annonc\/mdf146","DOI":"10.1093\/annonc\/mdf146"},{"issue":"5","key":"1934_CR24","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265. doi: 10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"issue":"4","key":"1934_CR25","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol Off J Am Soc Clin Oncol 17(4):1244","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5\u20136","key":"1934_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/10428199609052435","volume":"20","author":"A Aviles","year":"1996","unstructured":"Aviles A, Duque G, Talavera A, Guzman R (1996) Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 20(5\u20136):495\u2013499. doi: 10.3109\/10428199609052435","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1934_CR27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol Off J Am Soc Clin Oncol 15(3):1110\u20131117","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"1934_CR28","first-page":"951","volume":"86","author":"S Sacchi","year":"2001","unstructured":"Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G, GISL (2001) Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin\u2019s lymphoma. Haematologica 86(9):951\u2013958","journal-title":"Haematologica"},{"issue":"13","key":"1934_CR29","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, Haioun C, Brice P, Mahe B, Bouabdallah R, Audhuy B, Ferme C, Dartigeas C, Feugier P, Sebban C, Xerri L, Foussard C (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112(13):4824\u20134831. doi: 10.1182\/blood-2008-04-153189","journal-title":"Blood"},{"issue":"1","key":"1934_CR30","first-page":"68","volume":"10","author":"KT Echols","year":"2001","unstructured":"Echols KT, Gilles JM, Diro M (2001) Mycosis fungoides in pregnancy: remission after treatment with alpha-interferon in a case refractory to conventional therapy: a case report. J Matern-Fetal Med 10(1):68\u201370","journal-title":"J Matern-Fetal Med"},{"issue":"2","key":"1934_CR31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2141.1992.tb08202.x","volume":"81","author":"MR Baer","year":"1992","unstructured":"Baer MR, Ozer H, Foon KA (1992) Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 81(2):167\u2013169","journal-title":"Br J Haematol"},{"issue":"12","key":"1934_CR32","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/0959-8049(95)00374-6","volume":"31A","author":"VD Ferrari","year":"1995","unstructured":"Ferrari VD, Jirillo A, Lonardi F, Pavanato G, Bonciarelli G (1995) Pregnancy during alpha-interferon therapy in patients with advanced Hodgkin\u2019s disease. Eur J Cancer 31A(12):2121\u20132122","journal-title":"Eur J Cancer"},{"issue":"3","key":"1934_CR33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.reprotox.2011.11.003","volume":"33","author":"P Yazdani Brojeni","year":"2012","unstructured":"Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G (2012) A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 33(3):265\u2013268. doi: 10.1016\/j.reprotox.2011.11.003","journal-title":"Reprod Toxicol"},{"issue":"8","key":"1934_CR34","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"J-J Kiladjian","year":"2008","unstructured":"Kiladjian J-J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065\u20133072. doi: 10.1182\/blood-2008-03-143537","journal-title":"Blood"},{"issue":"2","key":"1934_CR35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","volume":"145","author":"C Mazzaro","year":"2009","unstructured":"Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G (2009) Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 145(2):255\u2013257. doi: 10.1111\/j.1365-2141.2008.07565.x","journal-title":"Br J Haematol"},{"issue":"18","key":"1934_CR36","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2009-06-228890","volume":"114","author":"EA Rossi","year":"2009","unstructured":"Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (2009) CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 114(18):3864\u20133871. doi: 10.1182\/blood-2009-06-228890","journal-title":"Blood"},{"issue":"14","key":"1934_CR37","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2009-10-250555","volume":"115","author":"C Xuan","year":"2010","unstructured":"Xuan C, Steward KK, Timmerman JM, Morrison SL (2010) Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115(14):2864\u20132871. doi: 10.1182\/blood-2009-10-250555","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-013-1934-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-013-1934-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T21:24:24Z","timestamp":1596835464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-013-1934-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1007\/s00277-013-1934-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,14]]}}}